^
Association details:
| Biomarker: | KRAS G12C |
|---|---|
| Cancer: | Solid Tumor |
| Drug: | mirdametinib (PD-0325901) (MEK inhibitor) + lifirafenib (BGB-283) (EGFR inhibitor, pan-RAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BeiGene and SpringWorks Announce Presentation of Preclinical Data Combining RAF Dimer Inhibitor Lifirafenib with MEK Inhibitor Mirdametinib and Provide Update on Ongoing Phase 1b/2 Clinical Trial
Published date:
06/22/2020
Excerpt:
Furthermore, in KRAS Q61K and KRAS G12C xenograft models, the combination demonstrated synergy as validated by pharmacodynamic pathway inhibition and tumor regressions.
